Leerink raised the firm’s price target on Quest Diagnostics (DGX) to $210 from $203 and keeps an Outperform rating on the shares. Q3 results were “another proof point of the near-Goldilocks environment in the lab space,” according to the analyst, who sees the stock action following “another strong quarter” as more likely a result of rotation than any new fundamental worries.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Morning Movers: General Motors and RTX higher following Q3 reports
- Quest Diagnostics: Strong Performance and Promising Outlook Justify Buy Rating
- Quest Diagnostics reports Q3 adjusted EPS $2.60, consensus $2.50
- Quest Diagnostics raises FY25 adjusted EPS view to $9.76-$9.84 from $9.63-$9.83
- Notable companies reporting before tomorrow’s open